Fate Therapeutics, Inc.
NASDAQ:FATEBiotechnology
-$0.00 today
- Market cap
- $122.39M
- Beta
- 2.52
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.08
Volume 1.87M
Average 2.92M
FATE Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Fate Therapeutics, Inc.NASDAQ: FATE
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $21.79M fell 25.2% year over year, behind the -23.9% change in trailing-twelve-month research & development. Sequentially, it fell 14.3% from the prior quarter. Over 3 fiscal years it compounded at -30.4% a year.
Context
- Research & development amounted to 1622.5% of revenue in FY2025, up 632.1 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -25.2% toward the trailing-twelve-month pace of -23.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 107.83M USD
- Year-over-year change
- -20.1%
- 4-year CAGR
- -15.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 107.83M | -20.1% |
| FY2024 | 2024-12-31 | 135M | -21.8% |
| FY2023 | 2023-12-31 | 172.6M | -46.1% |
| FY2022 | 2022-12-31 | 320.45M | +48.7% |
| FY2021 | 2021-12-31 | 215.52M | — |
Research & Development vs competitors
How FATE compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -23.9% is the 6th highest of 10, against a peer median of -9.9%.
- Research & development amounts to 1590.8% of revenue for FATE, versus a peer median of 547.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $312.43M USD | +226.5% | +70.8% | — | |
| LTM Mar 2026 | $114.68M USD | -37.7% | -16.4% | 622.7% | |
| LTM Mar 2026 | $100.48M USD | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $96.1M USD | -9.9% | +48.0% | — | |
| LTM Mar 2026 | $88.91M USD | -7.1% | -0.2% | — | |
| LTM Mar 2026 | $79.09M USD | -33.8% | +0.5% | 473.0% | |
| LTM Mar 2026 | $74.27M USD | +76.4% | +63.2% | — | |
| LTM Mar 2026 | $58.35M USD | -32.7% | +9.5% | — | |
| LTM Mar 2026 | $51.51M USD | -27.2% | -33.9% | — | |
| LTM Mar 2026 | CHF 46.97M CHF | -1.7% | -7.5% | — | |
| Peer median (excluding FATE) | — | -9.9% | +0.5% | 547.8% | |
Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.85M | 96.3M | 63.53M | 13.63M | 6.65M |
| Cost of Revenue | 5.85M | 13.76M | 157.19M | 118.53M | 12.9M |
| Gross Profit | 50M | 82.54M | (93.65M) | (104.9M) | (6.26M) |
| Gross Margin | 89.5% | 85.7% | -147.4% | -769.6% | -94.1% |
| Research & Development | 215.52M | 320.45M | 172.6M | 135M | 107.83M |
| Selling, General & Admin | 57.32M | 84.23M | 96.86M | 90.64M | 46.52M |
| Operating Expenses | 266.99M | 390.93M | 96.86M | 105.38M | 141.45M |
| Depreciation & Amortization | 5.85M | 13.76M | 18.28M | 18.96M | 9.3M |
| EBITDA | (206.3M) | (267.96M) | (142.65M) | (176.58M) | (127.02M) |
| EBITDA Margin | -369.4% | -278.3% | -224.5% | -1295.4% | -1911.2% |
| Operating Income | (216.99M) | (308.39M) | (190.51M) | (210.28M) | (147.7M) |
| Operating Margin | -388.6% | -320.2% | -299.9% | -1542.6% | -2222.4% |
| Interest Income | 1.31M | 5.84M | 17.19M | 17.29M | 11.05M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.84M | 26.67M | 29.58M | 24.01M | 11.39M |
| Income Before Tax | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Pre-Tax Margin | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Net Margin | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| EPS (Basic) | (2.24) | (2.91) | (1.64) | (1.64) | (1.15) |
| EPS (Diluted) | (2.24) | (2.91) | (1.64) | (1.64) | (1.15) |
| Weighted Avg Shares | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
| Weighted Avg Shares (Diluted) | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
Fate Therapeutics, Inc.
NASDAQ:FATE
Intrinsic Alpha fair value
Locked
Current Price
$1.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.